What Oncology Pharmacists Need to Know About ADCs in Solid Tumor Management

In this episode, hear Allison Butts, PharmD, BCOP and Danielle Roman, PharmD, BCOP, share their insights on the best practices for incorporating antibody–drug conjugates (ADCs) into clinical practice including:

• An overview of ADC structure and mechanism of action
• A topline review of data supporting the current FDA-approved indications for ADCs targeting HER2 and TROP-2 across multiple tumor types
• An in-depth look at common and serious adverse events with each approved ADC along with an overview of management strategies

Editor’s note: On June 23, 2025, the FDA granted accelerated approval for a new indication for datopotamab deruxtecan, one of the antibody drug conjugates discussed in this podcast. Datopotamab deruxtecan is now also approved for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received previous EGFR-targeted therapy and platinum-based chemotherapy. 

Program faculty:

Allison Butts, PharmD, BCOP
Pharmacist Manager, Oncology
Clinical Pharmacist, Breast Oncology
UK HealthCare
Markey Cancer Center
Lexington, Kentucky

Danielle Roman, PharmD, BCOP
Manager, Oncology Clinical Pharmacy Services
Allegheny Health Network
Pittsburgh, Pennsylvania

Program page:
https://bit.ly/4lr7cT6

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.